Improving outcomes in patients with adrenal insufficiency: a review of current and future treatments

References

• Dunlop D. Eighty-six cases of Addison's disease. Br Med J 1963;2:887-91
   PubMedGoogle Scholar
• Crown A, Lightman S. Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clin Endocrinol (Oxf) 2005;63:483-92
   PubMed Web of Science ®Google Scholar
• Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999;341:1013-20
   PubMed Web of Science ®Google Scholar
• Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab 2000;85:4650-6
   PubMed Web of Science ®Google Scholar
• Mason AS, Meade TW, Lee JA, Morris JN. Epidemiological and clinical picture of Addison's disease. Lancet 1968;2:744-7
   PubMed Web of Science ®Google Scholar
• Clapper A, Nashelsky M, Dailey M. Evaluation of serum cortisol in the postmortem diagnosis of acute adrenal insufficiency. Am J Forensic Med Pathol 2008;29:181-4
   PubMed Web of Science ®Google Scholar
• Hahner S, Loeffler M, Bleicken B, et al. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur J Endocrinol 2010;162:597-602
   PubMed Web of Science ®Google Scholar
• Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G. Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab 2006;91:4849-53
   PubMed Web of Science ®Google Scholar
• Bensing S, Brandt L, Tabaroj F, et al. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf) 2008;69:697-704
   PubMed Web of Science ®Google Scholar
• Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285-8
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357:425-31
   PubMed Web of Science ®Google Scholar
• Mills JL, Schonberger LB, Wysowski DK, et al. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr 2004;144:430-6
   PubMed Web of Science ®Google Scholar
• Gaillard RC, Mattsson AF, Akerblad AC, et al. Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol 2012;166:1069-77
   PubMed Web of Science ®Google Scholar
• Sherlock M, Reulen RC, Alonso AA, et al. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 2009;94:4216-23
   PubMed Web of Science ®Google Scholar
• Burman P, Mattsson AF, Johannsson G, et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab 2013;98:1466-75
   PubMed Web of Science ®Google Scholar
• Hahner S, Loeffler M, Fassnacht M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 2007;92:3912-22
   PubMed Web of Science ®Google Scholar
• Filipsson H, Monson JP, Koltowska-Haggstrom M, et al. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006;91:3954-61
   PubMed Web of Science ®Google Scholar
• Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 1994;120:207-10
   PubMed Web of Science ®Google Scholar
• Løvås K, Loge JH, Husebye ES. Subjective health status in Norwegian patients with Addison's disease. Clin Endocrinol (Oxf) 2002;56:581-8
   PubMed Web of Science ®Google Scholar
• Gurnell EM, Hunt PJ, Curran SE, et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab 2008;93:400-9
   PubMed Web of Science ®Google Scholar
• Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991;72:39-45
   PubMed Web of Science ®Google Scholar
• Kraan GP, Dullaart RP, Pratt JJ, et al. The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. J Clin Endocrinol Metab 1998;83:1247-52
   PubMed Web of Science ®Google Scholar
• Horrocks PM, Jones AF, Ratcliffe WA, et al. Patterns of ACTH and cortisol pulsatility over twenty-four hours in normal males and females. Clin Endocrinol (Oxf) 1990;32:127-34
   PubMed Web of Science ®Google Scholar
• Wallace WH, Crowne EC, Shalet SM, et al. Episodic ACTH and cortisol secretion in normal children. Clin Endocrinol (Oxf) 1991;34:215-21
   PubMed Web of Science ®Google Scholar
• Wilsson JD, Foster DW, Kronenberg HM, Larsen PR. Williams Textbook of Endocrinology, 10th edn. London: W.B. Saunders Company, 2002
   Google Scholar
• Debono M, Ghobadi C, Rostami-Hodjegan A, et al. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab 2009;94:1548-54
   PubMed Web of Science ®Google Scholar
• Newell-Price J, Trainer P, Perry L, et al. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1995;43:545-50
   PubMed Web of Science ®Google Scholar
• Darzy KH, Shalet SM. Absence of adrenocorticotropin (ACTH) neurosecretory dysfunction but increased cortisol concentrations and production rates in ACTH-replete adult cancer survivors after cranial irradiation for nonpituitary brain tumors. J Clin Endocrinol Metab 2005;90:5217-25
   PubMed Web of Science ®Google Scholar
• Van Cauter E, Leproult R, Kupfer DJ. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab 1996;81:2468-73
   PubMed Web of Science ®Google Scholar
• Knutsson U, Dahlgren J, Marcus C, et al. Circadian cortisol rhythms in healthy boys and girls: relationship with age, growth, body composition, and pubertal development. J Clin Endocrinol Metab 1997;82:536-40
   PubMed Web of Science ®Google Scholar
• Sharma M, Palacios-Bois J, Schwartz G, et al. Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry 1989;25:305-19
   PubMed Web of Science ®Google Scholar
• Zhao ZY, Xie Y, Fu YR, et al. Circadian rhythm characteristics of serum cortisol and dehydroepiandrosterone sulfate in healthy Chinese men aged 30 to 60 years. A cross-sectional study. Steroids 2003;68:133-8
   PubMed Web of Science ®Google Scholar
• Chrousos GP. The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351-62
   PubMed Web of Science ®Google Scholar
• Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003;348:727-34
   PubMed Web of Science ®Google Scholar
• Boonen E, Vervenne H, Meersseman P, et al. Reduced cortisol metabolism during critical illness. N Engl J Med 2013;368:1477-88
   PubMed Web of Science ®Google Scholar
• Perrot D, Bonneton A, Dechaud H, et al. Hypercortisolism in septic shock is not suppressible by dexamethasone infusion. Crit Care Med 1993;21:396-401
   PubMed Web of Science ®Google Scholar
• Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA 2009;106:4453-8
   PubMed Web of Science ®Google Scholar
• Dallman MF, la Fleur SE, Pecoraro NC, et al. Minireview: glucocorticoids – food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology 2004;145:2633-8
   PubMed Web of Science ®Google Scholar
• Dallman MF, Akana SF, Bhatnagar S, et al. Bottomed out: metabolic significance of the circadian trough in glucocorticoid concentrations. Int J Obes Relat Metab Disord 2000;24(Suppl 2):S40-6
   PubMed Web of Science ®Google Scholar
• Plat L, Leproult R, L'Hermite-Baleriaux M, et al. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab 1999;84:3082-92
   PubMed Web of Science ®Google Scholar
• Gangwisch JE. Epidemiological evidence for the links between sleep, circadian rhythms and metabolism. Obes Rev 2009;10(Suppl 2):37-45
   PubMed Web of Science ®Google Scholar
• Matthews K, Schwartz J, Cohen S, Seeman T. Diurnal cortisol decline is related to coronary calcification: CARDIA study. Psychosom Med 2006;68:657-61
   PubMed Web of Science ®Google Scholar
• Spath-Schwalbe E, Uthgenannt D, Korting N, et al. Sleep and wakefulness affect the responsiveness of the pituitary–adrenocortical axis to arginine vasopressin in humans. Neuroendocrinology 1994;60:544-8
   PubMed Web of Science ®Google Scholar
• Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab 2001;86:3787-94
   PubMed Web of Science ®Google Scholar
• Rodenbeck A, Hajak G. Neuroendocrine dysregulation in primary insomnia. Rev Neurol (Paris) 2001;157:S57-61
   PubMed Web of Science ®Google Scholar
• Born J, Spath-Schwalbe E, Schwakenhofer H, et al. Influences of corticotropin-releasing hormone, adrenocorticotropin, and cortisol on sleep in normal man. J Clin Endocrinol Metab 1989;68:904-11
   PubMed Web of Science ®Google Scholar
• Kumari M, Badrick E, Ferrie J, et al. Self-reported sleep duration and sleep disturbance are independently associated with cortisol secretion in the Whitehall II study. J Clin Endocrinol Metab 2009;94:4801-9
   PubMed Web of Science ®Google Scholar
• Steiger A, Holsboer F. Neuropeptides and human sleep. Sleep 1997;20:1038-52
   PubMed Web of Science ®Google Scholar
• Steiger A, von Bardeleben U, Herth T, Holsboer F. Sleep EEG and nocturnal secretion of cortisol and growth hormone in male patients with endogenous depression before treatment and after recovery. J Affect Disord 1989;16:189-95
   PubMed Web of Science ®Google Scholar
• Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992;267:1244-52
   PubMed Web of Science ®Google Scholar
• Liston C, Cichon JM, Jeanneteau F, et al. Circadian glucocorticoid oscillations promote learning-dependent synapse formation and maintenance. Nat Neurosci 2013;16:698-705
   PubMed Web of Science ®Google Scholar
• Lamia KA, Papp SJ, Yu RT, et al. Cryptochromes mediate rhythmic repression of the glucocorticoid receptor. Nature 2011;480:552-6
   PubMed Web of Science ®Google Scholar
• Bass J. Physiology: on time metabolism. Nature 2011;480:466-7
   PubMed Web of Science ®Google Scholar
• Forss M, Batcheller G, Skrtic S, Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency – a worldwide patient survey. BMC Endocr Disord 2012;12:8
   PubMed Web of Science ®Google Scholar
• Axelrod L. Glucocorticoid therapy. In: DeGrooth LJ, Jameson JC (eds.) Endocrinology. Philadelphia: Elsevier Saunders, 2006:2329-42
   Google Scholar
• Liddle GW. Clinical pharmacology of the anti-inflammatory steroids. Clin Pharmacol Ther 1961;2:615-35
   PubMed Web of Science ®Google Scholar
• Caldato MC, Fernandes VT, Kater CE. One-year clinical evaluation of single morning dose prednisolone therapy for 21-hydroxylase deficiency. Arq Bras Endocrinol Metabol 2004;48:705-12
   PubMedGoogle Scholar
• Stavreva DA, Wiench M, John S, et al. Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. Nat Cell Biol 2009;11:1093-102
   PubMed Web of Science ®Google Scholar
• McConnell EM, Bell PM, Ennis C, et al. Effects of low-dose oral hydrocortisone replacement versus short-term reproduction of physiological serum cortisol concentrations on insulin action in adult-onset hypopituitarism. Clin Endocrinol (Oxf) 2002;56:195-201
   PubMed Web of Science ®Google Scholar
• Husebye ES, Allolio B, Arlt W, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med 2014;275:104-15
   PubMed Web of Science ®Google Scholar
• Simon N, Castinetti F, Ouliac F, et al. Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. Clin Pharmacokinet 2010;49:455-63
   PubMed Web of Science ®Google Scholar
• Reynolds RM, Stewart PM, Seckl JR, Padfield PL. Assessing the HPA axis in patients with pituitary disease: a UK survey. Clin Endocrinol (Oxf) 2006;64:82-5
   PubMed Web of Science ®Google Scholar
• Løvås K, Gjesdal CG, Christensen M, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 2009;160:993-1002
   PubMed Web of Science ®Google Scholar
• Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf) 1997;46:263-8
   PubMed Web of Science ®Google Scholar
• Oelkers W. Adrenal insufficiency. N Engl J Med 1996;335:1206-12
   PubMed Web of Science ®Google Scholar
• Chernow B, Alexander HR, Smallridge RC, et al. Hormonal responses to graded surgical stress. Arch Intern Med 1987;147:1273-8
   PubMed Web of Science ®Google Scholar
• Burke CW. Adrenocortical insufficiency. Clin Endocrinol Metab 1985;14:947-76
   PubMedGoogle Scholar
• Arlt W, Allolio B. Adrenal insufficiency. Lancet 2003;361:1881-93
   PubMed Web of Science ®Google Scholar
• Quinkler M, Hahner S. What is the best long-term management strategy for patients with primary adrenal insufficiency? Clin Endocrinol (Oxf) 2012;76:21-5
   PubMed Web of Science ®Google Scholar
• Repping-Wuts HJ, Stikkelbroeck NM, Noordzij A, et al. A glucocorticoid education group meeting: an effective strategy for improving self-management to prevent adrenal crisis. Eur J Endocrinol 2013;169:17-22
   PubMed Web of Science ®Google Scholar
• Toothaker RD, Craig WA, Welling PG. Effect of dose size on the pharmacokinetics of oral hydrocortisone suspension. J Pharm Sci 1982;71:1182-5
   PubMed Web of Science ®Google Scholar
• Toothaker RD, Sundaresan GM, Hunt JP, et al. Oral hydrocortisone pharmacokinetics: a comparison of fluorescence and ultraviolet high-pressure liquid chromatographic assays for hydrocortisone in plasma. J Pharm Sci 1982;71:573-6
   PubMed Web of Science ®Google Scholar
• Bleicken B, Hahner S, Loeffler M, et al. Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol 2008;159:811-17
   PubMed Web of Science ®Google Scholar
• Kehlet H, Binder C, Blichert-Toft M. Glucocorticoid maintenance therapy following adrenalectomy: assessment of dosage and preparation. Clin Endocrinol (Oxf) 1976;5:37-41
   PubMed Web of Science ®Google Scholar
• Scott RS, Donald RA, Espiner EA. Plasma ACTH and cortisol profiles in Addisonian patients receiving conventional substitution therapy. Clin Endocrinol (Oxf) 1978;9:571-6
   PubMed Web of Science ®Google Scholar
• Feek CM, Ratcliffe JG, Seth J, et al. Patterns of plasma cortisol and ACTH concentrations in patients with Addison's disease treated with conventional corticosteroid replacement. Clin Endocrinol (Oxf) 1981;14:451-8
   PubMed Web of Science ®Google Scholar
• Groves RW, Toms GC, Houghton BJ, Monson JP. Corticosteroid replacement therapy: twice or thrice daily? J R Soc Med 1988;81:514-16
   PubMed Web of Science ®Google Scholar
• Blomgren J, Ekman B, Andersson PO, Arnqvist HJ. Non-physiological levels of circulating cortisol in growth hormone-treated hypopituitary adults after conventional cortisone substitution. Scand J Clin Lab Invest 2004;64:132-9
   PubMed Web of Science ®Google Scholar
• DeVile CJ, Stanhope R. Hydrocortisone replacement therapy in children and adolescents with hypopituitarism. Clin Endocrinol (Oxf) 1997;47:37-41
   PubMed Web of Science ®Google Scholar
• Laureti S, Falorni A, Santeusanio F. Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses. J Endocrinol Invest 2003;26:1071-5
   PubMed Web of Science ®Google Scholar
• Ekman B, Bachrach-Lindstrom M, Lindstrom T, et al. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency. Clin Endocrinol (Oxf) 2012;77:18-25
   PubMed Web of Science ®Google Scholar
• Bleicken B, Hahner S, Loeffler M, et al. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2010;72:297-304
   PubMed Web of Science ®Google Scholar
• Benson S, Neumann P, Unger N, et al. Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency. Eur J Endocrinol 2012;167:679-85
   PubMed Web of Science ®Google Scholar
• Behan LA, Rogers B, Hannon MJ, et al. Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients. Clin Endocrinol (Oxf) 2011;75:505-13
   PubMed Web of Science ®Google Scholar
• Riedel M, Wiese A, Schurmeyer TH, Brabant G. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes. Exp Clin Endocrinol 1993;101:106-11
   PubMedGoogle Scholar
• Harbeck B, Kropp P, Monig H. Effects of short-term nocturnal cortisol replacement on cognitive function and quality of life in patients with primary or secondary adrenal insufficiency: a pilot study. Appl Psychophysiol Biofeedback 2009;34:113-19
   PubMed Web of Science ®Google Scholar
• Arlt W, Rosenthal C, Hahner S, Allolio B. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf) 2006;64:384-9
   PubMed Web of Science ®Google Scholar
• Fadeev VV, Gitel EP, Mel'nichenko GA. The diurnal rhythm of adrenocorticotropic hormone secretion in the assessment of the adequacy of replacement therapy in primary chronic adrenal failure. Neurosci Behav Physiol 2001;31:237-42
   PubMedGoogle Scholar
• Løvås K, Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol 2007;157:109-12
   PubMed Web of Science ®Google Scholar
• Suliman AM, Freaney R, Smith TP, et al. The impact of different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2003;59:380-7
   PubMed Web of Science ®Google Scholar
• Maguire AM, Ambler GR, Moore B, et al. Prolonged hypocortisolemia in hydrocortisone replacement regimens in adrenocorticotrophic hormone deficiency. Pediatrics 2007;120:e164-71
   PubMed Web of Science ®Google Scholar
• MacGregor RR, Sheagren JN, Lipsett MB, Wolff SM. Alternate-day prednisone therapy. Evaluation of delayed hypersensitivity responses, control of disease and steroid side effects. N Engl J Med 1969;280:1427-31
   PubMed Web of Science ®Google Scholar
• Dunne FP, Elliot P, Gammage MD, et al. Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism. Clin Endocrinol (Oxf) 1995;43:623-9
   PubMed Web of Science ®Google Scholar
• Peacey SR, Guo CY, Robinson AM, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) 1997;46:255-61
   PubMed Web of Science ®Google Scholar
• Agha A, Liew A, Finucane F, et al. Conventional glucocorticoid replacement overtreats adult hypopituitary patients with partial ACTH deficiency. Clin Endocrinol (Oxf) 2004;60:688-93
   PubMed Web of Science ®Google Scholar
• Danilowicz K, Bruno OD, Manavela M, et al. Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitary 2008;11:279-85
   PubMed Web of Science ®Google Scholar
• Johannsson G, Bergthorsdottir R, Nilsson AG, et al. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol 2009;161:119-30
   PubMed Web of Science ®Google Scholar
• Johannsson G, Nilsson AG, Bergthorsdottir R, et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 2012;97:473-81
   PubMed Web of Science ®Google Scholar
• Newell-Price J, Whiteman M, Rostami-Hodjegan A, et al. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf) 2008;68:130-5
   PubMed Web of Science ®Google Scholar
• Verma S, Vanryzin C, Sinaii N, et al. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2010;72:441-7
   PubMed Web of Science ®Google Scholar
• Lennernas H, Skrtic S, Johannsson G. Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors. Expert Opin Drug Metab Toxicol 2008;4:749-58
   PubMed Web of Science ®Google Scholar
• Dressman JB, Thelen K, Jantratid E. Towards quantitative prediction of oral drug absorption. Clin Pharmacokinet 2008;47:655-67
   PubMed Web of Science ®Google Scholar
• Price JM, Davis SS, Wilding IR. Characterization of colonic transit of nondisintegrating tablets in healthy subjects. Dig Dis Sci 1993;38:1015-21
   PubMed Web of Science ®Google Scholar
• Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res 1991;8:360-4
   PubMed Web of Science ®Google Scholar
• Christensen FN, Davis SS, Hardy JG, et al. The use of gamma scintigraphy to follow the gastrointestinal transit of pharmaceutical formulations. J Pharm Pharmacol 1985;37:91-5
   PubMed Web of Science ®Google Scholar
• Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986;27:886-92
   PubMed Web of Science ®Google Scholar
• Basit AW. Advances in colonic drug delivery. Drugs 2005;65:1991-2007
   PubMed Web of Science ®Google Scholar
• Schiller C, Frohlich CP, Giessmann T, et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2005;22:971-9
   PubMed Web of Science ®Google Scholar
• Hebden JM, Gilchrist PJ, Blackshaw E, et al. Night-time quiescence and morning activation in the human colon: effect on transit of dispersed and large single unit formulations. Eur J Gastroenterol Hepatol 1999;11:1379-85
   PubMed Web of Science ®Google Scholar
• Pedersen BL, Brondsted H, Lennernas H, et al. Dissolution of hydrocortisone in human and simulated intestinal fluids. Pharm Res 2000;17:183-9
   PubMed Web of Science ®Google Scholar
• Naylor LJ, Bakatselou V, Dressman JB. Comparison of the mechanism of dissolution of hydrocortisone in simple and mixed micelle systems. Pharm Res 1993;10:865-70
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20
   PubMed Web of Science ®Google Scholar
• Schedl HP. Absorption of steroid hormones from the human small intestine. J Clin Endocrinol Metab 1965;25:1309-16
   PubMed Web of Science ®Google Scholar
• Lennernas H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007;37:1015-51
   PubMed Web of Science ®Google Scholar
• Faassen F, Kelder J, Lenders J, et al. Physicochemical properties and transport of steroids across Caco-2 cells. Pharm Res 2003;20:177-86
   PubMed Web of Science ®Google Scholar
• Yates CR, Chang C, Kearbey JD, et al. Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res 2003;20:1794-803
   PubMed Web of Science ®Google Scholar
• Tannergren C, Bergendal A, Lennernas H, Abrahamsson B. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol Pharm 2009;6:60-73
   PubMed Web of Science ®Google Scholar
• Hebden JM, Wilson CG, Spiller RC, et al. Regional differences in quinine absorption from the undisturbed human colon assessed using a timed release delivery system. Pharm Res 1999;16:1087-92
   PubMed Web of Science ®Google Scholar
• Price JM, Davis SS, Sparrow RA, Wilding IR. The effect of meal composition on the gastrocolonic response: implications for drug delivery to the colon. Pharm Res 1993;10:722-6
   PubMed Web of Science ®Google Scholar
• Toothaker RD, Welling PG. Effect of dose size on the pharmacokinetics of intravenous hydrocortisone during endogenous hydrocortisone suppression. J Pharmacokinet Biopharm 1982;10:147-56
   PubMedGoogle Scholar
• Derendorf H, Mollmann H, Barth J, et al. Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol 1991;31:473-6
   PubMed Web of Science ®Google Scholar
• Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005;44:61-98
   PubMed Web of Science ®Google Scholar
• Mah PM, Jenkins RC, Rostami-Hodjegan A, et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2004;61:367-75
   PubMed Web of Science ®Google Scholar
• Fleisher D, Li C, Zhou Y, et al. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 1999;36:233-54
   PubMed Web of Science ®Google Scholar
• Quinkler M, Hahner S, Johannsson G, Stewart PM. Saving lives of patients with adrenal insufficiency: a pan-European initiative? Clin Endocrinol (Oxf) 2014;80:319-21
   PubMed Web of Science ®Google Scholar
• Whitaker MJ, Debono M, Huatan H, et al. An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. Clin Endocrinol (Oxf) 2014;80:554-61
   Google Scholar
• Merza Z, Rostami-Hodjegan A, Memmott A, et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2006;65:45-50
   PubMed Web of Science ®Google Scholar